GLP-1 insurance coverage in 2026: what gets covered, what gets denied
Coverage climbs with employer size: 43 percent of the largest firms cover a GLP-1 for obesity (KFF 2025). Medicare covers two indications. Medicaid is state-by-state. We walk through every coverage path, the prior authorization process, the most common denial reasons, four appeal pathways, and payer templates for every major insurer.
Your path depends on your coverage: employer insurance means check your formulary for the obesity label; Medicare covers two specific indications (cardiovascular disease or sleep apnea); uninsured means cash-pay, starting at about $149 a month.
- 43% of the largest employers (5,000+ workers) cover a GLP-1 for obesity, up from 28% a year earlier (KFF 2025); coverage drops sharply at smaller firms. The rest cover only the diabetes brands or nothing for obesity.
- Prior authorization is the gate. First submissions are often denied. In ACA marketplace plans, 44 percent of appealed denials were reversed in 2023 (KFF, all categories). A denial is worth fighting.
- Medicare Part D covers two indications only: Wegovy for cardiovascular risk reduction, and Zepbound for moderate-to-severe sleep apnea. Neither for obesity alone. As of July 1, 2026, the Medicare GLP-1 Bridge is now live: a flat $50/month for Wegovy, Foundayo and the Zepbound pen for weight management outside Part D, for beneficiaries meeting CMS clinical criteria.
- HSA and FSA dollars are eligible for any GLP-1 with a prescription, cutting the effective cash cost by 25 to 40%.
- Manufacturer savings cards (commercial insurance only) drop the copay to as low as $25/mo. See the coupons and savings guide for every card, the NovoCare and LillyDirect cash programs, and the Medicare Bridge starting July 2026.
- If your plan excludes GLP-1s entirely, the fastest path is cash-pay compounded semaglutide. See the cost guide.
What insurance covers Wegovy
On commercial insurance, the plans most likely to cover Wegovy for obesity are large-employer plans that have elected the weight-management benefit; 43 percent of the largest firms cover it (KFF 2025). Whether your plan does comes down to your employer's formulary, not the insurer's name. Check your specific insurer on the payer coverage pages, then use the matching prior-authorization template. On Medicare, Wegovy is covered for cardiovascular risk today and at a flat $50 a month under the Medicare GLP-1 Bridge from July 1, 2026.
Every coverage path at a glance
| Coverage path | Typical out-of-pocket / mo | What unlocks it | Source |
|---|---|---|---|
| Commercial, obesity-covered plan | $25 to $100 copay | Approved PA + step therapy or comorbidity | KFF employer survey |
| Commercial, T2D coverage | $25 to $80 copay | A1c above 6.5 + ICD-10 E11.x | ADA Standards |
| Medicare Part D, Wegovy CV | $50 to $200 copay | Established CV disease + BMI 27+ | CMS Part D |
| Medicare Part D, Zepbound OSA | $50 to $200 copay | AHI 15+ + BMI 30+ | Zepbound OSA approval |
| FEHB FEP Blue (federal employees): coverage details | Tier 2 to 3 copay (plan-dependent) | OPM mandate + PA (BMI 30+ or 27+ with comorbidity) | OPM FEHB mandate |
| Medicaid, T2D path | $0 to $8 copay | State formulary + PA | State-by-state breakdown |
| Medicaid, obesity path | $0 to $8 copay (15 states) | State formulary + PA | State-by-state breakdown |
| HSA / FSA, any path | Tax savings 25 to 40% | Prescription + receipts | IRS Pub 502 |
The KFF employer survey is the canonical reference for commercial coverage rates. We update the state Medicaid breakdown quarterly and on every major state PDL change.
How commercial insurance covers GLP-1
Commercial insurance in 2026 covers GLP-1 in one of three patterns: covered for obesity with prior authorization the approval an insurer requires before it will pay for the drug, covered for type 2 diabetes only, or excluded for obesity-indication brands entirely. KFF's 2025 employer survey puts weight-loss GLP-1 coverage at 43 percent of the largest firms (5,000+ workers), up from 28 percent a year earlier, with about 30 percent at 1,000 to 4,999 workers and 16 percent at 200 to 999 (KFF). KFF does not survey GLP-1 coverage below 200 employees; smaller firms likely sit lower.
The single most important thing to check is your plan's formulary the list of drugs your plan will pay for, published by your insurer or PBM, not the insurer's general policy. Many UnitedHealthcare commercial plans cover Wegovy under their criteria; some employer plans carve out anti-obesity medications entirely. Both are technically “UnitedHealthcare.” For a payer-by-payer breakdown with the published policy citation for each, see does my insurance cover Wegovy or Zepbound, including the Wellcare Medicare GLP-1 coverage page. Plan-specific templates live in the PA letter library.
The prior authorization process, step by step
Every commercial plan that covers GLP-1 for obesity requires prior authorization (PA). The plan-by-plan templates and the filing workflow live in the PA letter library. In sequence: the prescriber submits the PA form with supporting documentation; the insurer's PBM pharmacy benefit manager reviews against policy criteria within 72 hours to 7 business days; the insurer returns approval, denial, or a request for additional information. If denied, the patient has 180 days to appeal.
What documentation the PA needs
Documentation makes or breaks the PA. Most plans require all of the following:
- BMI documented within the past 30 days (height and weight)
- Comorbidity diagnosis with the correct ICD-10 code (the numeric billing code that tells the insurer your diagnosis):
- E66.01 for morbid obesity
- I10 for hypertension
- E78.x for dyslipidemia
- G47.33 for sleep apnea
- E11.x for type 2 diabetes
- Six months of documented lifestyle intervention (dietitian notes, MyPlate logs, or a structured program)
- Prior anti-obesity medication trial or documented contraindication (phentermine, orlistat, naltrexone-bupropion, liraglutide)
- Treatment plan with target weight loss and monitoring schedule
PCOS patients
PCOS patients who meet the BMI threshold qualify via the obesity-with-comorbidity path. The PA letter should file under E66.9 (obesity) plus R73.03 (prediabetes) plus E28.2 (PCOS) as supporting context. Filing under E28.2 alone will be denied.
Common denial reasons and how to overturn them
Six denial categories cover the vast majority of GLP-1 denials: step therapy not met, BMI below threshold, no comorbidity documentation, no lifestyle intervention documented, formulary exclusion, and not medically necessary. The appeal letter library has plan-specific templates for the most-cited reasons.
The most overturnable denial is step-therapy-not-met when the patient has a documented contraindication or intolerance to the step-therapy drug (the less expensive drug the insurer requires you to try before approving the more expensive one). Each template walks through the trial evidence and the policy citation that supports the appeal.
The four appeal pathways
The Affordable Care Act and ERISA (the federal law governing employer health plans) give the patient four sequential appeal paths, walked through below. Templates for each denial reason live in the appeal letter library.
- Peer-to-peer review.The prescriber calls the insurer's medical director. Fast (often 5 business days), informal, and frequently successful when the prescriber can frame the trial evidence clinically. No GLP-1-specific overturn rate is published for this stage.
- First-level internal appeal. Written submission to the insurer. Insurer must respond within 30 days (standard) or 72 hours (expedited). In ACA marketplace plans, about 44 percent of appealed denials were reversed in 2023 (KFF), across all drug and service categories.
- External review by an IRO (Independent Review Organization, a third-party reviewer the insurer cannot influence). Mandatory under the ACA for medical-necessity denials. Free to the patient. Decisions are binding on the insurer. GLP-1-specific overturn rates for this stage are not published.
- State insurance commissioner complaint. The state regulator can investigate denials that appear to violate state insurance law. Slower path, lower overturn rate, but useful when the denial applies a criterion not in the published policy.
Medicaid coverage state by state
Federal Medicaid policy permits states to cover anti-obesity medications but does not require it. As of 2026, approximately 15 state Medicaid programs cover Wegovy or Zepbound for obesity with prior authorization; the other 35 states cover only the diabetes brands (Ozempic, Mounjaro) for patients with type 2 diabetes.
California Medi-Cal removed obesity-indication GLP-1 from its preferred drug list in mid-2025; Massachusetts and Pennsylvania expanded coverage in the same year. State-specific PA criteria, formulary status, and PA submission contacts for every state live at Medicaid GLP-1 coverage by state, for example Minnesota and Indiana. The Medicaid managed care PA pathway has additional steps; verify your assigned MCO's formulary before filing.
Medicare Part D coverage
Medicare Part D, under the 2003 Medicare Modernization Act, excludes drugs for weight loss. Two indication-specific exceptions opened in 2024. Wegovy carries a Part D-eligible indication for cardiovascular risk reduction in adults with established cardiovascular disease and BMI 27+, following the SELECT registration trial (published in NEJM, November 2023); the label was added in March 2024. Zepbound carries a Part D-eligible indication for moderate-to-severe obstructive sleep apnea in adults with obesity, following SURMOUNT-OSA; labeled December 2024.
As of July 1, 2026, the weight-loss exclusion has a workaround. The Medicare GLP-1 Bridge is now live: a CMS demonstration running through December 31, 2027 that furnishes Wegovy, Foundayo and the Zepbound pen at a flat $50 a month to Part D beneficiaries who meet clinical criteria (BMI 35+, or BMI 30+ with heart failure with preserved ejection fraction, uncontrolled hypertension or CKD stage 3a and up, or BMI 27+ with pre-diabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease), for weight-management prescriptions only. It operates outside the Part D benefit: no deductible applies, and the copay does not count toward out-of-pocket totals. What each Medicare path costs by indication, and the cash floor if none applies, is in the Medicare GLP-1 cost guide.
Medicare Advantage plans can layer additional benefits beyond Part D, and a small number of MA plans cover anti-obesity medications as a supplemental benefit. For Medicare Advantage members, the Wellcare Medicare GLP-1 coverage page shows plan-specific CV and OSA criteria. Also see Wegovy and Zepbound OSA coverage and our senior-focused overview.
Employer-sponsored plans and self-funded carve-outs
Two structural patterns matter for working-age patients. Fully-insured plans use the insurer's standard formulary: if Aetna covers Wegovy commercially, an Aetna fully-insured employer plan covers Wegovy. Self-funded plans where the employer bears the claim cost and the insurer only administers claims often carve out anti-obesity medications as a cost-control measure. The carve-out is visible on the plan's summary plan description (SPD). If the SPD lists anti-obesity medications as “not covered,” PA is futile; the appeal path runs through the employer benefits committee, not the insurer.
HSA, FSA and HRA
HSA, FSA, and HRA accounts are eligible payment sources for GLP-1 with a prescription, under IRS Publication 502. This applies to both branded and compounded medication, and to the membership fee at a licensed telehealth program. The tax savings are real: a $400/mo cash-pay program paid from an HSA in the 24% federal bracket plus 5% state plus FICA savings is about 33% cheaper than the same program paid from after-tax dollars.
When your insurance changes
Open enrollment, job changes, and ACA marketplace re-enrollment introduce coverage discontinuity risk. The continuity-of-care path lets a patient on a stable GLP-1 dose request a short-term coverage bridge under the new plan (typically 60 to 90 days) while a new PA is processed. Submit the request with the prior PA approval letter and a clinical note documenting current dose and response. Where the new plan does not cover GLP-1 at all, the bridge buys time to set up a cash-pay or manufacturer-direct path.
Payer-specific PA templates
We publish PA letter templates with payer-specific policy citations and submission instructions. Each template walks through the documentation checklist, the criteria the payer evaluates, and the language we have seen overturn denials. Full library at PA letter templates. The condition-specific framing matters: a PA for T2D goes to the diabetes-brand criteria; a PA for obesity goes to the obesity-brand criteria; a PA for CV risk reduction uses the SELECT language.
For plans where coverage is employer-elected, confirm the benefit exists before filing. Premera Blue Cross coverage for Wegovy and Highmark coverage for Wegovy and Zepbound (including the sleep apnea pathway) are two examples where employer election is the deciding factor. For the ACA marketplace, see ACA marketplace GLP-1 coverage. For regional plans, Independence Blue Cross GLP-1 coverage includes detailed PA criteria. For federal employees, see FEHB Blue Cross coverage for Wegovy and Zepbound.
How insurers actually decide
Insurers do not read the medical record from the top. The PBM clinical reviewer (often a PharmD or RN) runs the submission against a checklist from the insurer's policy bulletin. If every box is checked, approval. If a box is unchecked, it escalates or is denied. Think of the PA as a criteria-checklist match, not a narrative argument. The narrative belongs in the appeal letter; the PA itself is documentation.
Off-label and uncovered indications
GLP-1 prescribed for PCOS, NAFLD, or alcohol use disorder is off-label in 2026 and almost universally denied by commercial insurance. The standard path is to pivot to a covered indication the patient also qualifies for (obesity with comorbidity, T2D, or CV risk reduction) and prescribe under that label. NAFLD strategy: Zepbound and MASH.
Trial evidence and policy citations
The registration trials PA letters most often cite, in order of frequency:
- STEP-1 (Wegovy, NEJM 2021) for the obesity indication
- SURMOUNT-1 (Zepbound, NEJM 2022) for the obesity indication
- SELECT (Wegovy, NEJM 2023) for cardiovascular risk reduction
- SURMOUNT-OSA (Zepbound, NEJM 2024) for the sleep apnea indication
- FLOW (Ozempic, NEJM 2024) for the renal indication
- SURPASS (tirzepatide for T2D, NEJM and Lancet 2022 to 2023)
The federal external-review process is documented at healthcare.gov external review, and ERISA-plan appeal rules at the Department of Labor EBSA.
What to do next
If you have commercial insurance, start with the payer-specific template at PA templates. If you have been denied, match your denial reason to the appeal template and start with peer-to-peer review. For manufacturer savings cards (as low as $25/mo with commercial insurance), the NovoCare and LillyDirect cash programs, and the Medicare Bridge starting July 2026, see the GLP-1 coupons and savings guide. Programs that accept commercial insurance billing and coordinate prior authorization include Noom Med, Found, Knownwell, Calibrate (requires commercial insurance, about $224/mo all-in), WeightWatchers Clinic (about $99/mo with coverage), and Amazon Pharmacy (branded Wegovy and Zepbound at upfront cash prices; with eligible insurance the oral pill can drop to $25/mo). Mochi Health, Henry Meds, Hims, and Ro are cash-pay only for the medication.
If you are on Medicare, the path is indication-dependent: Wegovy for CV risk or Zepbound for OSA. If you are on Medicaid, start at your state's page. If your plan does not cover GLP-1 and you need a cash-pay path now, head to the cost pillar and the program chart.
Frequently asked questions
Does insurance cover Wegovy or Zepbound for weight loss?
Most commercial plans either cover both, cover one with a step-therapy hurdle, or cover neither for obesity. Coverage is plan-specific, not insurer-wide. UnitedHealthcare covers Wegovy on most commercial plans but excludes it from many employer carve-outs. Anthem coverage varies by state affiliate. The only way to know is to check your plan's formulary, not your insurer's general policy.
How long does prior authorization take?
Standard PA review windows run 72 hours (Cigna) to 5-7 business days (Aetna, UnitedHealthcare, Anthem). Expedited PA, requested when delay would cause clinical harm, is 24 to 72 hours. Most denials hit within the standard window. No published benchmark exists for GLP-1 first-pass approval rates; complete documentation is the strongest factor a patient controls.
What is the most common reason GLP-1 prior auths are denied?
Step therapy not met (the patient has not tried phentermine, orlistat or another preferred agent first) is the single most common denial. Insufficient documentation of six-month lifestyle intervention is second. BMI below the threshold or comorbidity not documented with an ICD-10 code is third. All three are reversible on appeal with the right documentation.
Can I appeal a denial?
Yes, and the appeal rate of GLP-1 denials is higher than for most drug categories. There are four appeal pathways: peer-to-peer review with the plan's medical director, formal first-level internal appeal, external review by an independent reviewer, and state insurance commissioner complaint. The first two are run by the insurer; the second two are run by a third party. In ACA marketplace plans, 44 percent of appealed denials were reversed in 2023 across all categories (KFF); structuring the appeal around the trial-evidence base improves the odds.
Does Medicare cover GLP-1 for weight loss?
Medicare Part D does not cover any drug for weight loss, under a 2003 federal statute. Wegovy is covered for cardiovascular risk reduction in patients with established cardiovascular disease (since March 2024). Zepbound is covered for moderate-to-severe obstructive sleep apnea with BMI 30 or above (since December 2024). Both require the specific indication, not the obesity label. Separately, from July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge demonstration furnishes Wegovy, Foundayo and the Zepbound pen at a flat $50 a month to Part D beneficiaries who meet CMS clinical criteria. It covers weight-management prescriptions only and operates outside the Part D benefit.
Does Medicaid cover GLP-1?
Roughly 15 state Medicaid programs cover Wegovy or Zepbound for obesity with prior authorization in 2026. The other 35 states cover only the diabetes brands (Ozempic, Mounjaro) for patients with type 2 diabetes. State-specific details and the policy citation for each state live on the medicaid-by-state pages.
Can I use HSA or FSA money for GLP-1?
Yes. GLP-1 prescribed by a licensed provider is an eligible medical expense for HSA, FSA, and HRA accounts. This applies to both branded and compounded medication, and to the program membership fee when the program is a licensed medical practice. Save the receipts; the documentation is usually a Letter of Medical Necessity from the prescriber.
What happens if my employer changes insurance plans mid-year?
Coverage continuity is the patient's responsibility. Most plans accept a continuity-of-care exception for 60 to 90 days if the new plan would otherwise deny PA on a drug the patient was stable on under the prior plan. Submit the exception request with the prior PA approval and a clinical note documenting current dose and response.
Does the appeal process cost anything?
Internal appeals (with the insurer) are free. External review by an Independent Review Organization (IRO) is also free to the patient under the Affordable Care Act; the insurer pays the IRO fee. State insurance commissioner complaints are free. The only real cost of the appeal cascade is time: roughly 30 to 90 days from denial to external review decision.
Which GLP-1 telehealth programs accept insurance?
Of the 32 GLP-1 telehealth programs GLP Chart tracks, twelve accept commercial insurance billing: Noom Med, 9amHealth, PlushCare, Form Health, Klarity Health, Knownwell, Found, Embla, Amazon Pharmacy, Calibrate, WeightWatchers Clinic, and Zealthy. PlushCare is typically the most cost-effective with coverage, running about $50/mo all-in (membership plus a typical commercial copay). Calibrate requires commercial insurance and runs about $224/mo all-in with medication billed to your plan. Mochi Health, Henry Meds, Hims, and Ro are cash-pay only for the medication. Programs that accept insurance coordinate prior authorization on your behalf and bill the GLP-1 medication to your plan; your out-of-pocket becomes your plan copay.
